Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials Pharmaceutical Investing
COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 Psychedelics Investing
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression Psychedelics Investing
Levitee Labs Publishes First Combined Revenue Figures for September 2021 and October 2021 Psychedelics Investing
Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 for the Treatment of Spinocerebellar Ataxia Psychedelics Investing
Levitee Labs Signs LOI to Acquire Controlling Interest in a R&D Compounding Pharmacy; Focus to be on Levitee-Branded Products Psychedelics Investing
COMPASS Pathways plc to announce third quarter 2021 financial results on 9 November 2021 Psychedelics Investing
NeonMind and SRx Health Solutions Announce Strategic Alliance to Establish Specialty Mental Health Clinics for Interventional Psychiatry Treatments Psychedelics Investing
Levitee Labs Announces Gold Sponsorship of Wonderland Psychedelic Conference in Miami Psychedelics Investing
NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine Psychedelics Investing
